Catalyst Pharmaceuticals Inc
NASDAQ:CPRX

Watchlist Manager
Catalyst Pharmaceuticals Inc Logo
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Watchlist
Price: 21.48 USD 1.7% Market Closed
Market Cap: 2.6B USD
Have any thoughts about
Catalyst Pharmaceuticals Inc?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

17.7
Current
12.6
Median
4.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
17.7
=
Enterprise Value
2.2B USD
/
EBITDA
122.4m USD
All Countries
Close
EBITDA Growth
US
Catalyst Pharmaceuticals Inc
NASDAQ:CPRX
Average EV/EBITDA: 17.2
17.7
48%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -219 796.6 N/A
US
Abbvie Inc
NYSE:ABBV
15.3
29%
US
Amgen Inc
NASDAQ:AMGN
17.5
62%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
24.1
43%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
16%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -514.1 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.9
35%
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.5 N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
10.3
2-Years Forward
EV/EBITDA
10.4
3-Years Forward
EV/EBITDA
12.2

See Also

Discover More